Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Safety of the current drug treatments for vitiligo
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4598105
Author(s) Lotti, Torello; Agarwal, Komal; Podder, Indrashis; Satolli, Francesca; Kassir, Martin; Schwartz, Robert A.; Wollina, Uwe; Grabbe, Stephan; Navarini, Alexander A.; Mueller, Simon M.; Goldust, Mohamad
Author(s) at UniBasel Navarini, Alexander
Year 2020
Title Safety of the current drug treatments for vitiligo
Journal Expert Opinion on Drug Safety
Volume 19
Number 4
Pages / Article-Number 499-511
Keywords Vitiligo; contraindications; safety; treatment
Abstract Introduction; : Vitiligo is an acquired depigmenting skin disorder adversely affecting the patient's quality of life. Despite the presence of several treatment modalities, ranging from medical to physical to surgical options, none is curative. Each modality has its own drawbacks and side effects. Thus, the treatment modality needs to be tailored for each individual patient taking into consideration the disease characteristics and also its efficacy and safety to obtain a favorable risk-benefit ratio.; Areas covered; : This review highlights the different treatment modalities utilized in vitiligo up until 4 November 2019 along with their adverse effects and contraindications, if any.; Expert opinion; : All the medications have their own adverse effects and contraindications. We have included the most commonly used topical corticosteroids, which may result in striae, cutaneous atrophy, and tachyphylaxis, to the recently introduced biologics, which may induce hypersensitivity reactions, systemic toxicities, and even malignancies. However, more long-term studies are needed to assess the safety of these medications, especially the newer ones, to provide a safe and effective treatment for this disorder.
Publisher Taylor & Francis
ISSN/ISBN 1474-0338 ; 1744-764X
edoc-URL https://edoc.unibas.ch/76714/
Full Text on edoc No
Digital Object Identifier DOI 10.1080/14740338.2020.1729737
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/32067513
ISI-Number WOS:000520345600001
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.348 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
01/05/2024